Patents Assigned to UCL Biomedica PLC
-
Patent number: 9655925Abstract: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumor cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.Type: GrantFiled: November 21, 2013Date of Patent: May 23, 2017Assignee: UCL BIOMEDICA PLCInventor: Mark Lowdell
-
Publication number: 20140079678Abstract: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.Type: ApplicationFiled: November 21, 2013Publication date: March 20, 2014Applicant: UCL Biomedica PLCInventor: Mark LOWDELL
-
Patent number: 8637308Abstract: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumor cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.Type: GrantFiled: August 31, 2012Date of Patent: January 28, 2014Assignee: UCL Biomedica PLCInventor: Mark Lowdell
-
Publication number: 20120328587Abstract: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: UCL Biomedica PLCInventor: Mark LOWDELL
-
Patent number: 7820769Abstract: A copolymer comprising (a) one or more pendant group segments and (b) one or more polyol segments, each of said segments being linked to one or more further segments which may be the same or different, wherein said one or more pendant group segments are the same or different and are selected from: (i) siloxane segments; (ii) segments containing phosphoryl choline or a derivative or analogue thereof; (iii) segments containing a di- or trifluoromethyl group; (iv) heparin-like segments containing a group of formula (XII) D-N?N—Ar—SO3???(XII) wherein D is an aliphatic or aromatic group and Ar—SO3? comprises one or more linked aryl and/or heteroaryl groups, at least one of the aryl and/or heteroaryl groups having an SO3? substituent; and (v) segments containing a group of formula (I) [P]n?-[Lys]n-Lys-[Spacer]-Lys-[Al]x??(I) wherein: [Al] is an inert amino acid; x is 0, 1, 2 or 3; [Spacer] is a fatty acid, amino acid, peptide or PEG; [P]n?-[Lys]n is a dendritic structure formed from n lysine groups and termType: GrantFiled: January 20, 2005Date of Patent: October 26, 2010Assignee: UCL Biomedica PLCInventors: Alexander Seifalian, Henryk Salacinski, Kaila Srai, Bala Ramesh, Arnold Darbyshire, Steve Hancock
-
Patent number: 7598421Abstract: The invention provides a lipid of general formula (I) or (II): wherein X1, X2 and R1 to R5 are as defined herein. Such lipids are used to form complexes with a biologically-active material such as a nucleic acid, peptide or small molecule for delivering the biologically-active material to cells. The complexes may incorporate an integrin-binding peptide and, when the biologically-active material is DNA, thereby constitute a LID complex.Type: GrantFiled: November 8, 2004Date of Patent: October 6, 2009Assignee: UCL Biomedica PLCInventors: Helen C. Hailes, Alethea B. Tabor, John B. Wong, Michael Pilkington-Miksa, Stephen L. Hart, Christopher A. Hurley
-
Publication number: 20090069331Abstract: Compounds of formula (I) have been found to be useful as inhibitors of DDAH.Type: ApplicationFiled: November 11, 2005Publication date: March 12, 2009Applicant: UCL Biomedica PLC c/o Finance Division University College of LondonInventors: Patrick John Thompson Vallance, James Mitchell Leiper, David Lawrence Selwood, Sharon Rossiter, Basil Hartzoulakis
-
Patent number: 7494496Abstract: A device is provided which can act as one component of an anastomosis-forming assembly, i.e. as an anastomosis button. The device comprises a plurality of elongate members having a first, introduction configuration in which they are substantially aligned with one another, and a second, use configuration in which they are disposed at an angle to one another. For example, there may be two such elongate members, which, in the use configuration, form a cross. The device comprises means, for example, a tensionable thread, for bringing the elongate members into the use configuration.Type: GrantFiled: November 16, 2004Date of Patent: February 24, 2009Assignee: UCL BioMedica PLcInventors: Christopher Paul Swain, Charles Alexander Mosse
-
Patent number: 7442374Abstract: This invention relates to a method for treating or preventing (including immunising against) post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).Type: GrantFiled: July 19, 2004Date of Patent: October 28, 2008Assignee: UCL BioMedica PlcInventors: Oscar Adelmo Bottasso, Graham McIntyre, Cynthia Ann Stanford, John Lawson Stanford
-
Patent number: 7413728Abstract: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.Type: GrantFiled: November 12, 2004Date of Patent: August 19, 2008Assignee: UCL Biomedica PLCInventors: Graham McIntyre, John Lawson Stanford, Cynthia Ann Stanford, Oscar Adelmo Bottasso
-
Publication number: 20070104735Abstract: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.Type: ApplicationFiled: November 12, 2004Publication date: May 10, 2007Applicant: UCL BIOMEDICA PLCInventors: Graham Mcintyre, John Stanford, Cynthia Stanford, Oscar Bottasso
-
Publication number: 20060269935Abstract: A method for determining the dosage regime of a drug suitable for use in the treatment of a neurological condition in a subject, which method comprises typing the SCN1A gene of the subject. The method may be used to determine the dosage regime of an anti-epileptic drug (AED) in a subject. A subject may be treated in accordance with the dosage regime determined using such a method.Type: ApplicationFiled: March 17, 2006Publication date: November 30, 2006Applicant: UCL Biomedica PLCInventors: Sarah Tate, Gianpiero Cavalleri, Stephanie Schorge, Sanjay Sisodiya, Nicholas Wood, David Goldstein